
A Senate panel holding hearings this week on the nomination of Randall Tobias, head of the Office of the U.S. Global AIDS Coordinator, to become the new director of all U.S. foreign aid is expected to question Tobias on his push for overseas abstinence programs to slow the spread of HIV, CQ Today reports. Members of the Senate Foreign Relations Committee are expected to question Tobias on whether abstinence is an effective HIV prevention tool in developing countries that have different cultural practices than the United States and other Western nations and whether U.S. money earmarked for abstinence education is being spent wisely.
Tobias, the former CEO of drugmaker Eli Lilly, also is expected to be questioned on his opposition to using generic anti-HIV drugs to fight HIV in poor nations. AIDS advocates say that requiring U.S.-funded HIV treatment programs to use expensive brand-name drugs severely restricts the amount of medications that can be bought and distributed.
Tobias was nominated by Secretary of State Condoleezza Rice in January to head the U.S. Agency for International Development and to be the first director of foreign assistance at the State Department, a move that would make Tobias a deputy secretary of state. He is expected to be approved by the full Senate later this month. (Advocate.com)
These comments are reproduced as written by visitors to this Web site. They have not been edited for content, grammar, or spelling. The viewpoints appearing here are those of the writer, and do not necessarily reflect the opinion or views of advocate.com, The Advocate, or its affiliates.
Be the first to comment on this story.
If you would like to submit a comment for posting, please fill out the form above.
All comments submitted via this form are subject to posting or publication. (To send a private letter to an Advocate editor or writer, please use the e-mail button at the top of the page, or use snail mail.) If you would like your comment considered for publication in The Advocate magazine, please include your full name, your city of residence, and a phone number where you can be reached during business hours so that we can confirm your identity. Your e-mail address and telephone number are strictly confidential and will not be shared or used for any purpose other than to contact you about your comment.
See the Contact page for sending comments for reasons other than responding to Advocate editorial and news stories.
Please note that comments sent by fax or snail mail are unlikely to be posted, although they will be considered for publication along with all letters received via e-mail or via this Web page. Comments that chiefly concern Advocate.com content will be considered for posting only on the Web site. The Advocate reserves the right to edit submitted comments for grammar, spelling, obscenities, or libel; we will, however, do our best to preserve the original comment's style and intent. Comments considered for publication in The Advocate magazine may also be edited for length.